DX-002 (Singlomics Biopharmaceuticals)

N/A

Report date: 2025/06/30 16:21:48

Base Information

Drug NameDX-002 (Singlomics Biopharmaceuticals)
Drug Alias NameDX-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-Triggering receptor expressed on myeloid cells 1
TargetsTriggering receptor expressed on myeloid cells 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSinglomics Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinglomics Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A